PIK3CA and breast cancer: Rodriguez et al. [140] evaluated the utility of ctDNA in the diagnosis of early breast cancer patients by comparing the PIK3CA and TP53 mutations of fresh tissue biopsies and plasma samples using amplicon-based SafeSEQ (Sysmex Inostics) technology and NGS TruSeq custom amplicon low input panel (Illumina).